Why the study?
Renal angiosarcomas are rare malignancies comprising less than 1% of all kidney tumors, with approximately 70 published cases.
This case highlights that JAK2V617F may be a potential driver mutation in rare renal angiosarcomas.
Answers are grounded in this paper and cite their sources.
Renal angiosarcoma with concurrent JAK2 MPN is rare; leaves open shared molecular drivers and need for systematic profiling.
Renal angiosarcomas are rare malignancies with approximately 70 published cases and comprise less than 1% of all kidney tumors. We present an elderly male who was found to have a large 10cm kidney mass and underwent a left radical nephrectomy. Pathology revealed a renal angiosarcoma and unfortunately 3 months later was found to have metastatic disease in the liver. He was incidentally found to have a JAK2 positive myeloproliferative neoplasm at the same time. Molecular testing on the angiosarcoma revealed a JAK2V617F mutation. He was treated with standard of care chemotherapy; initially with paclitaxel and then anthracyclines. He also received liverdirected therapy with Y90 with stable disease. He unfortunately passed away due to an unrelated illness. Our case highlights a rare type of kidney malignancy and that JAK2V617F is a potential driver mutation in angiosarcomas.
No takes yet. Share an insight, caveat, or question.
Kapoor et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: